JNJ-42153605 | CAS#1254977-87-1 | PAM mGlu2

JNJ-42153605
new

featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526854

CAS#: 1254977-87-1

Description: JNJ-42153605 is a potent and selective mGlu2 receptor PAM with an acceptable pharmacokinetic profile in rodent and nonrodent species. JNJ-42153605 showed centrally mediated in vivo effectivity in models sensitive to mGlu2 receptor modulation such as sleep−wake electroencephalogram (sw-EEG) in rats,34 showing suppressed REM sleep during the first 4 h after oral administration of a 3 mg/kg dose.

Chemical Structure

JNJ-42153605

CAS# 1254977-87-1

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 526854
Name: JNJ-42153605
CAS#: 1254977-87-1
Chemical Formula: C22H23F3N4
Exact Mass: 400.19
Molecular Weight: 400.449
Elemental Analysis: C, 65.99; H, 5.79; F, 14.23; N, 13.99

Price and Availability

Size	Price	Availability
25mg	USD 250	2 Weeks
50mg	USD 450	2 Weeks
100mg	USD 750	2 Weeks
200mg	USD 1250	2 Weeks
500mg	USD 2250	2 Weeks
1g	USD 3250
2g	USD 5450	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: JNJ-42153605; JNJ 42153605; JNJ42153605.

IUPAC/Chemical Name: 3-(Cyclopropylmethyl)-7-(4-phenyl-1-piperidinyl)-8-(trifluoromethyl)[1,2,4]triazolo[4,3-a]pyridine

InChi Key: BQAVZGJJQFJSMW-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H23F3N4/c23-22(24,25)20-18(10-13-29-19(14-15-6-7-15)26-27-21(20)29)28-11-8-17(9-12-28)16-4-2-1-3-5-16/h1-5,10,13,15,17H,6-9,11-12,14H2

SMILES Code: FC(C1=C(N2CCC(C3=CC=CC=C3)CC2)C=CN4C1=NN=C4CC5CC5)(F)F

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	JNJ-42153605 is a positive allosteric modulator of the metabotropic glutamate 2 (mGlu2) receptor with an EC50 of 17 nM.
In vitro activity:	Consistent with the effects of an allosteric potentiator, JNJ-42153605 shifts the concentration-response curve of glutamate to the left (Fig 1C left panel), increasing the potency of glutamate up to ∼25-fold. At the human mGluR2, the EC50 of glutamate decreases from ∼10 to 0.5 μM with the addition of 3 μM JNJ-42153605. Reference: PLoS One. 2015 Dec 11;10(12):e0144017. https://pubmed.ncbi.nlm.nih.gov/26658273/
In vivo activity:	JNJ-40411813, JNJ-42153605, and LY404039 dose dependently inhibited spontaneous locomotion and PCP- and scopolamine-induced hyperlocomotion but not d-amphetamine-induced hyperlocomotion (Fig. 2; Table 2) in mice. Reference: Pharmacol Res Perspect. 2015 Mar;3(2):e00097. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324682/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMF	30.0	74.92
	DMF:PBS (pH 7.2) (1:3)	0.3	0.62
	DMSO	10.3	25.81
	Ethanol	10.0	24.97

Preparing Stock Solutions

The following data is based on the product molecular weight 400.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Ahnaou A, Lavreysen H, Tresadern G, Cid JM, Drinkenburg WH. mGlu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary Efficacy on Sleep Measures in Rats. PLoS One. 2015 Dec 11;10(12):e0144017. doi: 10.1371/journal.pone.0144017. PMID: 26658273; PMCID: PMC4684355. 2. Lavreysen H, Langlois X, Donck LV, Nuñez JM, Pype S, Lütjens R, Megens A. Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813. Pharmacol Res Perspect. 2015 Mar;3(2):e00097. doi: 10.1002/prp2.97. Epub 2015 Jan 30. PMID: 25692027; PMCID: PMC4324682. 3. Cid JM, Tresadern G, Vega JA, de Lucas AI, Matesanz E, Iturrino L, Linares ML, Garcia A, Andrés JI, Macdonald GJ, Oehlrich D, Lavreysen H, Megens A, Ahnaou A, Drinkenburg W, Mackie C, Pype S, Gallacher D, Trabanco AA. Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. J Med Chem. 2012 Oct 25;55(20):8770-89. doi: 10.1021/jm3010724. Epub 2012 Oct 16. PMID: 23072213.
In vitro protocol:	1. Ahnaou A, Lavreysen H, Tresadern G, Cid JM, Drinkenburg WH. mGlu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary Efficacy on Sleep Measures in Rats. PLoS One. 2015 Dec 11;10(12):e0144017. doi: 10.1371/journal.pone.0144017. PMID: 26658273; PMCID: PMC4684355.
In vivo protocol:	1. Lavreysen H, Langlois X, Donck LV, Nuñez JM, Pype S, Lütjens R, Megens A. Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813. Pharmacol Res Perspect. 2015 Mar;3(2):e00097. doi: 10.1002/prp2.97. Epub 2015 Jan 30. PMID: 25692027; PMCID: PMC4324682. 2. Cid JM, Tresadern G, Vega JA, de Lucas AI, Matesanz E, Iturrino L, Linares ML, Garcia A, Andrés JI, Macdonald GJ, Oehlrich D, Lavreysen H, Megens A, Ahnaou A, Drinkenburg W, Mackie C, Pype S, Gallacher D, Trabanco AA. Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. J Med Chem. 2012 Oct 25;55(20):8770-89. doi: 10.1021/jm3010724. Epub 2012 Oct 16. PMID: 23072213.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Ahnaou A, Lavreysen H, Tresadern G, Cid JM, Drinkenburg WH. mGlu2 Receptor
Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards
Their Primary Efficacy on Sleep Measures in Rats. PLoS One. 2015 Dec
11;10(12):e0144017. doi: 10.1371/journal.pone.0144017. eCollection 2015. PubMed
PMID: 26658273; PubMed Central PMCID: PMC4684355.

2: Lavreysen H, Langlois X, Donck LV, Nuñez JM, Pype S, Lütjens R, Megens A.
Preclinical evaluation of the antipsychotic potential of the mGlu2-positive
allosteric modulator JNJ-40411813. Pharmacol Res Perspect. 2015 Mar;3(2):e00097.
doi: 10.1002/prp2.97. Epub 2015 Jan 30. PubMed PMID: 25692027; PubMed Central
PMCID: PMC4324682.

3: Wyckhuys T, Wyffels L, Langlois X, Schmidt M, Stroobants S, Staelens S. The
[18F]FDG μPET readout of a brain activation model to evaluate the metabotropic
glutamate receptor 2 positive allosteric modulator JNJ-42153605. J Pharmacol Exp
Ther. 2014 Aug;350(2):375-86. doi: 10.1124/jpet.114.213959. Epub 2014 Jun 4.
PubMed PMID: 24898267.

4: Megens AA, Hendrickx HM, Hens KA, Talloen WJ, Lavreysen H. mGlu(2)
receptor-mediated modulation of conditioned avoidance behavior in rats. Eur J
Pharmacol. 2014 Mar 15;727:130-9. doi: 10.1016/j.ejphar.2014.01.044. Epub 2014
Jan 30. PubMed PMID: 24486391.

5: Cid JM, Tresadern G, Vega JA, de Lucas AI, Matesanz E, Iturrino L, Linares ML,
Garcia A, Andrés JI, Macdonald GJ, Oehlrich D, Lavreysen H, Megens A, Ahnaou A,
Drinkenburg W, Mackie C, Pype S, Gallacher D, Trabanco AA. Discovery of
3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4
,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic
glutamate 2 receptor. J Med Chem. 2012 Oct 25;55(20):8770-89. doi:
10.1021/jm3010724. Epub 2012 Oct 16. PubMed PMID: 23072213.

Your view history

JNJ-42153605 new featured